RecruitingPhase 1Phase 2NCT05377996
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Sponsor
Day One Biopharmaceuticals, Inc.
Enrollment
360 participants
Start Date
Aug 15, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
A Study of Emi-Le in Participants with Solid Tumors
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new cancer drug called XMT-1660 — a type of antibody-drug conjugate, which is like a guided missile that targets cancer cells and delivers chemotherapy directly to them — in people with advanced or recurring solid tumors.
**You may be eligible if...**
- You have an advanced or recurrent solid tumor that has come back or progressed
- You are in good overall health (ECOG performance status 0 or 1)
- You have a tumor that can be measured or assessed by standard imaging
- You can provide a tumor tissue sample (either from a previous biopsy or a new one)
**You may NOT be eligible if...**
- You have untreated or active brain metastases that are not stable
- Your tumor tissue is not available and you cannot undergo a new biopsy
- Your overall health status is too poor to tolerate experimental treatment
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEmi-Le
Emi-Le will be administered through a vein in your arm or port catheter (intravenously)
Locations(26)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05377996
Related Trials
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT0607838444 locations
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT054122257 locations
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
NCT069702754 locations
A Study of a Side Effects and Resource Navigation Program for People With Cancer
NCT076468478 locations
Identifying Genetic Targets in Gynecological Tumors
NCT071693961 location